Article
Immunology
Behnam Sadeghi, Olle Ringden, Britt Gustafsson, Markus Castegren
Summary: Acute respiratory distress syndrome (ARDS) is a life-threatening lung disease. Mesenchymal stromal cells (MSCs) have been evaluated as a therapy for ARDS, and the use of MSCs for ARDS induced by Covid-19 has shown positive results. Clinical and experimental studies have demonstrated the effectiveness of MSCs in treating sepsis and ARDS.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cell Biology
Chang Liu, Kun Xiao, Lixin Xie
Summary: This review discusses the pathogenesis of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and the biological characteristics and mechanisms of mesenchymal stromal cells (MSCs) in the treatment of ALI/ARDS.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Immunology
Olle Ringden, Guido Moll, Britt Gustafsson, Behnam Sadeghi
Summary: This article summarizes the authors' more than 20 years of scientific experience in the clinical use of MSCs and DSCs in different clinical settings. MSCs and DSCs have significant effects on the immune system and coagulation, and show potential clinical efficacy in conditions such as acute GvHD, ARDS, and hemorrhages.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Pharmacology & Pharmacy
Dragan Primorac, Martin Cemerin, Vid Matisic, Vilim Molnar, Marko Strbad, Lenart Girandon, Lucija Zenic, Miomir Knezevic, Stephen Minger, Denis Polancec
Summary: The COVID-19 pandemic has had a significant impact globally and the overaggressive immune reaction in response to the virus can lead to ARDS. Mesenchymal stromal cell therapy presents a potential treatment option for severe patients.
Article
Cell & Tissue Engineering
Kamal Hezam, Chen Wang, Enze Fu, Manqian Zhou, Yue Liu, Hui Wang, Lihong Zhu, Zhibo Han, Zhong-Chao Han, Ying Chang, Zongjin Li
Summary: This study used PGE2 to prime MSCs and investigated their therapeutic potential in ALI models. The results showed that PGE2-MSCs effectively ameliorated lung injury and reduced total cell numbers, neutrophils, macrophages, and protein levels in BALF. Furthermore, PGE2 priming improved the therapeutic efficacy of MSCs through M2 macrophage polarization and cytokine production regulation.
STEM CELL RESEARCH & THERAPY
(2023)
Review
Pharmacology & Pharmacy
Sara Rolandsson Enes, Anna D. Krasnodembskaya, Karen English, Claudia C. Dos Santos, Daniel J. Weiss
Summary: Advancements in cell-based therapies for lung diseases and critical illnesses show promise, but translating efficacy from preclinical to clinical settings has been challenging due to limited understanding of MSCs' interaction with the host environment. Challenges for MSC cell therapies include cell sources, dosing, disease targets, donor variability, and cell product manufacturing.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Critical Care Medicine
Ellen A. Gorman, Jennifer Rynne, Hannah J. Gardiner, Anthony J. Rostron, Jonathan Bannard-Smith, Andrew M. Bentley, David Brealey, Christina Campbell, Gerard Curley, Mike Clarke, Ahilanadan Dushianthan, Phillip Hopkins, Colette Jackson, Kallirroi Kefela, Anna Krasnodembskaya, John G. Laffey, Cliona McDowell, Margaret McFarland, Jamie McFerran, Peter McGuigan, Gavin D. Perkins, Jonathan Silversides, Jon Smythe, Jacqui Thompson, William S. Tunnicliffe, Ingeborg D. M. Welters, Laura Amado-Rodriguez, Guillermo Albaiceta, Barry Williams, Manu Shankar-Hari, Daniel F. McAuley, Cecilia M. O'Kane
Summary: This study investigated the safety and efficacy of ORBCEL-C (CD362-enriched, umbilical cord-derived MSCs) in COVID-19-related ARDS. The results showed that ORBCEL-C did not improve surrogate outcomes of pulmonary organ dysfunction. Evaluation: 7/10.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2023)
Article
Cell & Tissue Engineering
Beth H. Shaz, Bryan D. Kraft, Jesse D. Troy, Emily Poehlein, Lingye Chen, Lynn Cheatham, Raha Manyara, Khalid Hanafy, Linda Brown, Margaret Scott, Ralph Palumbo, Frank Vrionis, Joanne Kurtzberg
Summary: This study explores the feasibility and safety of using allogeneic human umbilical cord derived mesenchymal stromal cells (hCT-MSCs) for treating COVID-19-related acute respiratory distress syndrome (ARDS). The results show that this treatment method is feasible and safe in clinical practice, without any related adverse reactions. However, further research is needed to explore its safety and efficacy.
STEM CELLS TRANSLATIONAL MEDICINE
(2023)
Article
Cell & Tissue Engineering
Hamid Reza Aghayan, Fatemeh Salimian, Atefeh Abedini, Samrand Fattah Ghazi, Masud Yunesian, Sepideh Alavi-Moghadam, Jalil Makarem, Keivan Majidzadeh-A, Ali Hatamkhani, Maryam Moghri, Abbas Danesh, Mohammad Reza Haddad-Marandi, Hassan Sanati, Fereshteh Abbasvandi, Babak Arjmand, Pourya Azimi, Ardeshir Ghavamzadeh, Ramin Sarrami-Forooshani
Summary: This study aimed to evaluate the safety of intravenous injection of placenta-derived mesenchymal stem cells (PL-MSCs) in patients with COVID-19-induced acute respiratory distress syndrome (ARDS). The results demonstrated that the administration of PL-MSCs was safe and feasible, with no adverse events observed. There were no significant differences in clinical and laboratory parameters between the treatment and control groups. Further studies are needed to evaluate the efficacy of this treatment modality using higher cell doses and repeated injections.
STEM CELL RESEARCH & THERAPY
(2022)
Review
Immunology
Huikang Xu, Shiying Sheng, Weiwei Luo, Xiaofang Xu, Zhaocai Zhang
Summary: Acute respiratory distress syndrome (ARDS) is a serious condition characterized by inflammatory lung injury and immune system disturbance. Researchers have used latent class analysis and targeted treatment to improve ARDS therapy, and sepsis-induced ARDS is particularly difficult to treat.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Medicine, General & Internal
Qian Hu, Shu Zhang, Yue Yang, Jia-Qi Yao, Wen-Fu Tang, Christopher J. Lyon, Tony Ye Hu, Mei-Hua Wan
Summary: “Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are common and life-threatening lung diseases associated with acute and severe inflammation. Study on extracellular vesicles (EVs) has shown their potential role in regulating pulmonary inflammation, including ALI/ARDS, and predicting the development of these diseases.”
MILITARY MEDICAL RESEARCH
(2022)
Article
Medicine, General & Internal
Katia Nunes da Silva, Priscila Carvalho Guedes Pinheiro, Andre Luiz Nunes Gobatto, Rogerio da Hora Passos, Bruno Diaz Paredes, Luciana Souza de Arago Franca, Carolina Kymie Vasques Nonaka, Beatriz Barreto-Duarte, Mariana Araujo-Pereira, Rafael Tiburcio, Fernanda Ferreira Cruz, Gabriele Louise Soares Martins, Bruno B. Andrade, Hugo Caire de Castro-Faria-Neto, Patricia Rieken Macedo Rocco, Bruno Solano de Freitas Souza
Summary: This case report demonstrated the reduction of both lung inflammation and fibrosis in a critically ill COVID-19 patient after MSC therapy, leading to significant clinical improvement and discharge from the hospital.
FRONTIERS IN MEDICINE
(2021)
Article
Cell & Tissue Engineering
Yuling Luo, Shanhui Ge, Qingui Chen, Shan Lin, Wanmei He, Mian Zeng
Summary: This study explored whether overexpression of FoxM1 promotes the therapeutic effect of BMSCs on ARDS. The results showed that FoxM1 overexpression significantly decreased pathological variations, protein concentration, oxidative stress, and cytokine levels. Furthermore, FoxM1 enhanced the protective effect of BMSCs on endothelial cell injury through the activation of the Wnt/beta-catenin signaling pathway.
STEM CELL RESEARCH & THERAPY
(2023)
Article
Cell Biology
Paulius Valiukevicius, Justinas Maciulaitis, Dalia Pangonyte, Vitalija Sirataviciute, Katarzyna Kluszczynska, Ugne Kuzaityte, Ruta Insodaite, Ieva Ciapiene, Ramune Grigaleviciute, Vilma Zigmantaite, Astra Vitkauskiene, Romaldas Maciulaitis
Summary: This study investigates the therapeutic potential of human placental mesenchymal stem cells (P-MSCs) and their extracellular vesicles (EVs) in a murine model of acute respiratory distress syndrome (ARDS). The results show that both P-MSC and EV therapy can reduce lung injury, decrease neutrophil infiltration, and improve alveolar barrier integrity. Analyses of cytokines and gene expression reveal that both treatments accelerate inflammation resolution in lung tissue. Biodistribution studies indicate that the therapeutic effects of intraperitoneal P-MSC therapy are mainly mediated by soluble factors.
Review
Medicine, Research & Experimental
Wendi Wang, Wei Lei, Lina Jiang, Siqi Gao, Shijun Hu, Zi-Gang Zhao, Chun-Yu Niu, Zhen-Ao Zhao
Summary: MSCs, derived from various sources and with low immunogenicity, have been widely used for the treatment of ARDS. Recent studies suggest that MSCs can ameliorate ARDS through multiple mechanisms, such as modulating immune/inflammatory cells, attenuating endoplasmic reticulum stress, and inhibiting pulmonary fibrosis.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Letter
Critical Care Medicine
Vincenzo Russotto, Giacomo Bellani, John G. Laffey
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2023)
Article
Engineering, Industrial
Evismar Andrade, Leo R. Quinlan, Richard Harte, Bronwyn Reid-McDermott, Frank Kirrane, Enda Fallon, Martina Kelly, Tony Hall, Michael Scully, John Laffey, Patrick Pladys, Ethel Ryan, Dara Byrne, Gearoid OLaighin
Summary: This study developed an online training platform to train clinicians on the use of a critical care medical device and carried out a preliminary evaluation of the platform via a case study. The results showed that participants were able to use and interpret the device interface and were overall satisfied with the training platform, perceiving it as an efficient and effective method for training.
APPLIED ERGONOMICS
(2023)
Article
Anesthesiology
Vincenzo Russotto, Jean Baptiste Lascarrou, Elena Tassistro, Matteo Parotto, Laura Antolini, Philippe Bauer, Konstanty Szuldrzynski, Luigi Camporota, Christian Putensen, Paolo Pelosi, Massimiliano Sorbello, Andy Higgs, Robert Greif, Giacomo Grasselli, Maria G. Valsecchi, Roberto Fumagalli, Giuseppe Foti, Pietro Caironi, Giacomo Bellani, John G. Laffey, NTUBE Study Investigators
Summary: Videolaryngoscopy is associated with higher first-pass intubation success rates in critically ill patients and does not increase the risk of major adverse events.
BRITISH JOURNAL OF ANAESTHESIA
(2023)
Letter
Critical Care Medicine
Michael G. Madden, Bairbre A. McNicholas, John G. Laffey
INTENSIVE CARE MEDICINE
(2023)
Article
Cell & Tissue Engineering
Hector Gonzalez, Sean McCarthy, Claire Masterson, Declan Byrnes, Ignacio Sallent, Emma Horan, Stephen J. Elliman, Gabriele Vella, Adriele P. Mello, Johnatas D. Silva, Anna D. Krasnodembskaya, Ronan MacLoughlin, John G. Laffey, Daniel O'Toole
Summary: In this study, the therapeutic potential of directly nebulised MSC-EVs in mitigating Escherichiacoli-induced pneumonia was investigated. The results showed that MSC-EVs retained their immunomodulatory and wound healing capacity after nebulisation. Treatment with IV or nebulised MSC-EVs reduced the severity of LPS-induced lung injury and E. coli-induced pneumonia.
STEM CELL RESEARCH & THERAPY
(2023)
Letter
Critical Care Medicine
Tai Pham, Leo Heunks, Giacomo Bellani, Laurent Brochard, John Laffey
LANCET RESPIRATORY MEDICINE
(2023)
Article
Critical Care Medicine
Bruno Francois, Simon Lambden, Tom Fivez, Sebastien Gibot, Marc Derive, Jean-Marie Grouin, Margarita Salcedo-Magguilli, Jeremie Lemarie, Nicolas De Schryver, Ville Jalkanen, Tarik Hicheur, Jean-Jacques Garaud, Valerie Cuvier, Ricard Ferrer, Morten Bestle, Ville Pettila, Jean-Paul Mira, Camille Bouisse, Emmanuelle Mercier, Joris Vermassen, Vincent Huberlant, Isabelle Vinatier, Nadia Anguel, Mitchell Levy, Pierre-Francois Laterre
Summary: This study aimed to investigate whether the TREM-1 inhibitor nangibotide could improve outcomes in patients with septic shock. The findings suggest that both low and high doses of nangibotide did not significantly improve the condition of patients with septic shock compared to placebo.
LANCET RESPIRATORY MEDICINE
(2023)
Article
Respiratory System
Bairbre A. McNicholas, Miguel Ibarra-Estrada, Yonatan Perez, Jie Li, Ivan Pavlov, Aileen Kharat, David L. Vines, Oriol Roca, David Cosgrave, Claude Guerin, Stephan Ehrmann, John G. Laffey
Summary: Awake prone positioning (APP) gained attention during the COVID-19 pandemic for treating acute hypoxaemic respiratory failure. It improves oxygenation and has similar effects as invasive ventilation in patients with moderate-severe acute respiratory distress syndrome. Randomised controlled studies in COVID-19 patients have conflicting outcomes, but evidence suggests that more severe hypoxaemic patients benefit most from APP when managed in higher care environments and being prone for several hours.
EUROPEAN RESPIRATORY REVIEW
(2023)
Article
Medicine, General & Internal
Hector E. Gonzalez, Sean D. McCarthy, Claire Masterson, John G. Laffey, Ronan MacLoughlin, Daniel O'Toole
Summary: Mesenchymal stem cell secretome has strong immunomodulatory effects and can be delivered to the lung through nebulization, showing therapeutic potential for inflammatory diseases such as pneumonia ARDS.
FRONTIERS IN MEDICINE
(2023)
Article
Urology & Nephrology
Marina Wainstein, Nicholas Spyrison, Danyang Dai, Moji Ghadimi, Jonathan S. Chavez-Iniguez, Lilia Rizo-Topete, Barbara Wanjiru Citarella, Laura Merson, Jason D. Pole, Rolando Claure-Del Granado, David W. Johnson, S. Shrapnel
Summary: There is a lack of research on the relationship between COVID-19 and acute kidney injury (AKI) in low- and low-middle income countries. This study found that AKI incidence was highest in LLMIC, with lower rates of dialysis and poorer patient outcomes.
KIDNEY INTERNATIONAL REPORTS
(2023)
Article
Anesthesiology
David M. Hannon, Tim Jones, Jack Conolly, Conor Judge, Talha Iqbal, Atif Shahzad, Michael Madden, Frank Kirrane, Peter Conneely, Brian H. Harte, Martin O'Halloran, John G. Laffey
Summary: Developed and assessed a system for shared ventilation using clinically available components to individualize tidal volumes. The system allowed accurate and reproducible titration of tidal volumes to each limb over a range of ventilator settings and simulated lung conditions.
BMC ANESTHESIOLOGY
(2023)
Article
Medicine, General & Internal
Declan Byrnes, Claire Masterson, Jack Brady, Shahd Horie, Sean D. D. McCarthy, Hector Gonzalez, Daniel O'Toole, John Laffey
Summary: This study aimed to evaluate the efficacy of delayed administration of bone marrow (BM), adipose (AD), and umbilical cord (UC) derived mesenchymal stromal cells (MSC) in antibiotic resistant pneumonia-induced sepsis. In vitro experiments showed that BM-, AD-, and UC-MSCs accelerated epithelial healing, increased phagocytosis, and reduced epithelial injury. Delayed MSC therapy in pre-clinical sepsis enhanced resolution of lung injury and modulated immune cell profile. BM and UC-MSCs were more effective than AD-MSCs, and naive MSCs had a more favorable effect profile compared to pre-activated MSCs.
FRONTIERS IN MEDICINE
(2023)
Article
Critical Care Medicine
Marius Troseid, Jose R. Arribas, Lambert Assoumou, Aleksander Rygh Holten, Julien Poissy, Vida Terzic, Fulvia Mazzaferri, Jesus Rodriguez Bano, Joe Eustace, Maya Hites, Michael Joannidis, Jose-Artur Paiva, Jean Reuter, Isabel Puentmann, Thale D. J. H. Patrick-Brown, Elin Westerheim, Katerina Nezvalova-Henriksen, Lydie Beniguel, Tuva Borresdatter Dahl, Maude Bouscambert, Monika Halanova, Zoltan Peterfi, Sotirios Tsiodras, Michael Rezek, Matthias Briel, Serhat Unal, Martin Schlegel, Florence Ader, Karine Lacombe, Cecilie Delphin Amdal, Serge Rodrigues, Kristian Tonby, Alexandre Gaudet, Lars Heggelund, Joy Mootien, Asgeir Johannessen, Jannicke Horjen Moller, Beatriz Diaz Pollan, Anders Aune Tveita, Anders Benjamin Kildal, Jean-Christophe Richard, Olav Dalgard, Victoria Charlotte Simensen, Aliou Balde, Lucie de Gastines, Marta del Alamo, Burc Aydin, Fridtjof Lund-Johansen, Mary-Anne Trabaud, Alpha Diallo, Bente Halvorsen, John-Arne Rottingen, Evelina Tacconelli, Yazdan Yazdanpanah, Inge C. Olsen, Dominique Costagliola
Summary: The study conducted a placebo-controlled trial of baricitinib in severe/critical COVID cases. The results showed that baricitinib did not reduce mortality within 60 days, and there may be safety risks in vaccinated participants, which require further investigation.
Meeting Abstract
Critical Care Medicine
Jie Li, Jian Luo, Ivan Pavlov, Yonatan Perez, Aileen Kharat, Elsa Tavernier, David Vines, Oriol Roca, Bairbre McNicholas, Miguel Ibarra-Estrada, John Laffey, Claude Guerin, Stephan Ehrmann
CRITICAL CARE MEDICINE
(2023)
Article
Critical Care Medicine
Bairbre A. A. McNicholas, Emanuele Rezoagli, Andrew J. J. Simpkin, Sankalp Khanna, Jacky Y. Y. Suen, Pauline Yeung, Daniel Brodie, Gianluigi Li Bassi, Tai Pham, Giacomo Bellani, John F. F. Fraser, John Laffey
Summary: AKI is a common and serious complication in COVID-19 patients, with different characteristics and outcomes compared to non-COVID-19 ARDS patients.